JP2021527694A - 腫瘍溶解性ウイルスを用いた処置 - Google Patents

腫瘍溶解性ウイルスを用いた処置 Download PDF

Info

Publication number
JP2021527694A
JP2021527694A JP2020570967A JP2020570967A JP2021527694A JP 2021527694 A JP2021527694 A JP 2021527694A JP 2020570967 A JP2020570967 A JP 2020570967A JP 2020570967 A JP2020570967 A JP 2020570967A JP 2021527694 A JP2021527694 A JP 2021527694A
Authority
JP
Japan
Prior art keywords
cancer
virus
tumor
inhibitors
ctla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570967A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019243847A5 (https=
JP2021527694A5 (https=
Inventor
スチュアート コフィン，ロバート
Original Assignee
レプリミュン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レプリミュン リミテッド filed Critical レプリミュン リミテッド
Publication of JP2021527694A publication Critical patent/JP2021527694A/ja
Publication of JPWO2019243847A5 publication Critical patent/JPWO2019243847A5/ja
Publication of JP2021527694A5 publication Critical patent/JP2021527694A5/ja
Priority to JP2024076002A priority Critical patent/JP2024105452A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020570967A 2018-06-21 2019-06-21 腫瘍溶解性ウイルスを用いた処置 Pending JP2021527694A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076002A JP2024105452A (ja) 2018-06-21 2024-05-08 腫瘍溶解性ウイルスを用いた処置

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862687910P 2018-06-21 2018-06-21
US201862687931P 2018-06-21 2018-06-21
US201862687920P 2018-06-21 2018-06-21
US201862687881P 2018-06-21 2018-06-21
US62/687,920 2018-06-21
US62/687,931 2018-06-21
US62/687,881 2018-06-21
US62/687,910 2018-06-21
PCT/GB2019/051769 WO2019243847A1 (en) 2018-06-21 2019-06-21 Treatment using oncolytic virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076002A Division JP2024105452A (ja) 2018-06-21 2024-05-08 腫瘍溶解性ウイルスを用いた処置

Publications (3)

Publication Number Publication Date
JP2021527694A true JP2021527694A (ja) 2021-10-14
JPWO2019243847A5 JPWO2019243847A5 (https=) 2022-06-24
JP2021527694A5 JP2021527694A5 (https=) 2022-06-24

Family

ID=67262783

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570967A Pending JP2021527694A (ja) 2018-06-21 2019-06-21 腫瘍溶解性ウイルスを用いた処置
JP2024076002A Pending JP2024105452A (ja) 2018-06-21 2024-05-08 腫瘍溶解性ウイルスを用いた処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076002A Pending JP2024105452A (ja) 2018-06-21 2024-05-08 腫瘍溶解性ウイルスを用いた処置

Country Status (6)

Country Link
US (1) US20210252135A1 (https=)
EP (1) EP3810191A1 (https=)
JP (2) JP2021527694A (https=)
CN (1) CN112601547A (https=)
CA (1) CA3103371A1 (https=)
WO (1) WO2019243847A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3778881A1 (en) 2016-01-08 2021-02-17 Replimune Limited Modified oncolytic virus
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CA3156880A1 (en) * 2019-11-06 2021-05-14 Memgen, Inc. Replication-enhanced oncolytic adenoviruses
CN115605586B (zh) * 2020-04-07 2024-09-06 深圳市华药康明生物药业有限责任公司 工程化溶瘤腺病毒
WO2021235685A1 (ko) * 2020-05-20 2021-11-25 바이로큐어 주식회사 암 예방 또는 치료용 약학적 조성물
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
CN113244411B (zh) * 2021-06-25 2021-09-17 诺赛联合(北京)生物医学科技有限公司 一种基因修饰的溶瘤病毒诱导ctl细胞方法及其在肿瘤治疗的用途
CN113699122B (zh) * 2021-08-31 2023-10-20 中国科学院大学宁波华美医院 一种多基因融合溶瘤腺病毒及其构建方法和应用
CN114350709A (zh) * 2021-09-18 2022-04-15 梁亚龙 一种经修饰的溶瘤性腺病毒载体
CN116836283B (zh) * 2022-05-17 2024-05-07 苏州万灏生物科技有限公司 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用
WO2023226942A1 (zh) * 2022-05-23 2023-11-30 上海药明康德新药开发有限公司 一种编码免疫刺激因子和抗免疫检查点抗体的重组hsv-1载体
WO2024082263A1 (zh) * 2022-10-21 2024-04-25 上海鑫湾生物科技有限公司 一种响应缺氧环境控制病毒复制的系统及其用途
CN115976109B (zh) * 2022-11-07 2025-06-27 武汉大学 一种靶向降解gbp蛋白的hsv-1溶瘤病毒及其制备与应用
CN116555191B (zh) * 2023-05-26 2024-09-17 东北农业大学 编码白细胞介素24和粒细胞-巨噬细胞集落刺激因子的新城疫病毒在肿瘤治疗中的应用
CN117797263B (zh) * 2023-11-29 2024-06-18 华南农业大学 一种药物组合物、药物和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511549A (ja) * 2009-11-20 2013-04-04 インフィニティー ファーマシューティカルズ， インコーポレイテッド ヘッジホッグ関連癌の治療のための方法及び組成物
JP2016509045A (ja) * 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
WO2017118865A1 (en) * 2016-01-08 2017-07-13 Replimune Limited Oncolytic virus strain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
ES2704632T3 (es) * 2011-09-08 2019-03-19 Univ New York Virus de herpes simplex oncolítico y sus usos terapéuticos
US9789182B2 (en) 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511549A (ja) * 2009-11-20 2013-04-04 インフィニティー ファーマシューティカルズ， インコーポレイテッド ヘッジホッグ関連癌の治療のための方法及び組成物
JP2016509045A (ja) * 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
WO2017118865A1 (en) * 2016-01-08 2017-07-13 Replimune Limited Oncolytic virus strain
WO2017118864A1 (en) * 2016-01-08 2017-07-13 Replimune Limited Modified oncolytic viurs
WO2017118866A1 (en) * 2016-01-08 2017-07-13 Replimune Limited Engineered virus

Also Published As

Publication number Publication date
EP3810191A1 (en) 2021-04-28
US20210252135A1 (en) 2021-08-19
JP2024105452A (ja) 2024-08-06
CA3103371A1 (en) 2019-12-26
CN112601547A (zh) 2021-04-02
WO2019243847A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
JP7295192B2 (ja) 改変された腫瘍溶解性ウイルス
JP7813310B2 (ja) 改変ウイルス
JP2021527694A (ja) 腫瘍溶解性ウイルスを用いた処置
HK40088422A (en) Oncolytic virus strain

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240620

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240709

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241025